2018 Prix Galien USA Awards: Recognizing Innovative Excellence

On October 25th, 2018, The Prix Galien USA Committee honored excellence in the biopharmaceutical and medical industry for research, development, and innovation at its 12th annual Prix Galien Awards Gala, held at the American Museum of Natural History in New York City. In recognition of the development and discovery of products that improve the human condition, a committee of highly accomplished scientific leaders, including four Nobel Laureates, recognized winners in three categories: “Best Pharmaceutical Product,” “Best Biotechnology Product,” and “Best Medical Technology.” This year, the Committee chose two winners in the Biotechnology category.

Celgene-Agios won Best Pharmaceutical Product for IDHFA; Best Biotechnology Product went to Kite, a Gilead Company for Yescarta and Novartis Pharmaceutical for Kymriah; and Boston Scientific won Best Medical Technology for WATCHMAN.

“The Committee had the unique opportunity to award four winners across three categories due to the extremely high caliber of scientific rigor demonstrated by this year’s candidates,” said Bruno Cohen, Chairman of the Galien Foundation. “All winners have made crucial contributions to the advancement of scientific understanding and improved outcomes for humankind. We are proud to honor their tireless work and unrelenting spirit.”

In addition to the 2018 product innovation awards, this year’s Roy Vagelos Pro Bono Humanum Award was accepted by Bill and Melinda Gates, co-chairs of the Bill & Melinda Gates Foundation. Widely recognized as champions of the world’s most economically disadvantaged individuals, Bill and Melinda Gates were selected by the Committee for their impressive humanitarian efforts and advocacy for gender equity. Visit www.galienfoundation.org to learn more.

Katey Owen (right) accepting the “Roy Vagelos Pro Bono Humanum” award on behalf of Bill & Melinda Gates with Roy Vagelos (center) and Dr. Desmond-Hellmann.
Pascal Touchon, Senior Vice President, Global Head of Cell and Gene Oncology, Novartis. Novartis was the second recipient of the “Best Biotechnology Product” award on behalf of Kymriah.
David Schenkein, MD, CEO, Agios Pharmaceuticals and Krishnan Viswanadhan, Vice President of Global Alliances, Celgene Corporation (center) receive “Best Pharmaceutical Product” on behalf of IDHIFA.
Tim Ley, Research & Design Manager, Interventional Cardiology, Boston Scientific Corporation accepting the “Best Medical Technology” award.
William Go, MD, PhD, Vice President, Clinical Development, Kite, a Gilead Company (center) accepting the “Best Biotechnology Product” award.


You May Also Like

Learning to Speak HEOR

As one formulary decision-maker told us: “Recent regulation guidance on FDAMA114 frees up pharma ...

ELITE 2018 Strategist Jerrold McRae of Pfizer Inc.

Jerrold McRae Senior Manager, U.S. Marketing Pfizer Inc. Re-thinking Conversations About Chronic Pain What ...

Second Thoughts On Patient Segmentation Studies

The enduring appeal that high-priced segmentation research holds for pharmaceutical marketers is difficult to ...